AstraZeneca Beats Q3 Profit Estimates and Launches $1.5B Annual Savings Restructuring Plan

AstraZeneca reported better-than-expected third-quarter results on October 30, with total revenue rising 7% to $16.21 billion, driven by double-digit growth across its oncology, respiratory and immunology, and rare disease units. Core earnings per share reached $2.02, up 23% from $1.64 a year earlier, topping analyst estimates. CFO Aradhana Sarin highlighted the oncology and immunology portfolio as the primary engine of the outperformance.

Alongside the earnings release, the company unveiled a restructuring plan projected to generate $1.5 billion in annual savings, at a one-time cost of up to $2 billion spread over three years. AstraZeneca said it intends to reinvest those savings into its drug pipeline, which spans more than 180 active projects. The plan comes after a series of late-stage clinical trial setbacks and rising pressure from generic drug competition.

Despite the restructuring, AstraZeneca reaffirmed its long-term targets of $80 billion in annual revenue and 20 new medicine launches by 2030. The nine-month 2026 total revenue stood at $46.88 billion, up 8% year over year, suggesting the company remains on a trajectory consistent with those ambitions.